WO2002088091A3 - Inhibitors of human rhinovirus 2a cysteine protease - Google Patents

Inhibitors of human rhinovirus 2a cysteine protease Download PDF

Info

Publication number
WO2002088091A3
WO2002088091A3 PCT/US2002/013270 US0213270W WO02088091A3 WO 2002088091 A3 WO2002088091 A3 WO 2002088091A3 US 0213270 W US0213270 W US 0213270W WO 02088091 A3 WO02088091 A3 WO 02088091A3
Authority
WO
WIPO (PCT)
Prior art keywords
human rhinovirus
inhibitors
halo
amino
cysteine protease
Prior art date
Application number
PCT/US2002/013270
Other languages
French (fr)
Other versions
WO2002088091A2 (en
Inventor
Raymond A Kim
David Shivak
Dongxu Sun
Original Assignee
Iconix Pharm Inc
Raymond A Kim
David Shivak
Dongxu Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconix Pharm Inc, Raymond A Kim, David Shivak, Dongxu Sun filed Critical Iconix Pharm Inc
Publication of WO2002088091A2 publication Critical patent/WO2002088091A2/en
Publication of WO2002088091A3 publication Critical patent/WO2002088091A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula I are effective inhibitors of human rhinovirus 2A protease: (I) where R1 is H, lower alkyl, lower alkenyl, lower alkynyl, lower acyl, or lower acyloxy, substituted with 0-3 substituents selected from the group consisting of OH, halo, amino, nitro; R2 is H, lower alkyl, OH, halo, or amino; R3, R4, R5, R6, and R7 are each independently H, halo, OH, amino, nitro, lower alkyl, aryl, aralkyl, lower alkoxy, or lower alkylamino; or a pharmaceutically acceptable salt thereof.
PCT/US2002/013270 2001-04-26 2002-04-26 Inhibitors of human rhinovirus 2a cysteine protease WO2002088091A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28708301P 2001-04-26 2001-04-26
US60/287,083 2001-04-26

Publications (2)

Publication Number Publication Date
WO2002088091A2 WO2002088091A2 (en) 2002-11-07
WO2002088091A3 true WO2002088091A3 (en) 2002-12-19

Family

ID=23101374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013270 WO2002088091A2 (en) 2001-04-26 2002-04-26 Inhibitors of human rhinovirus 2a cysteine protease

Country Status (1)

Country Link
WO (1) WO2002088091A2 (en)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] TANAKA E. ET AL.: "Comparison of trimethadione and antipyrine as indicators of oxidative drug metabolizing capacity in man", XP002958361, accession no. STN Database accession no. 1989:508460 *
DATABASE CAPLUS [online] USUI Y. ET AL.: "Fungicides. XII. Synthesis and antifungal activity of halogen-substituted phenylpyrazolone derivatives", XP002958362, accession no. STN Database accession no. 1967:411452 *
EUR. J. OF CLIN. PHARM., vol. 36, no. 6, 1989, pages 29 - 32 *
YAKAGAKU ZASSHI, vol. 87, no. 1, 1967, pages 38 - 42 *

Also Published As

Publication number Publication date
WO2002088091A2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
GB2392154B (en) Protein Kinase Inhibitors
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
WO2003043961A3 (en) Modulators of rho c activity
TW200500362A (en) 5-membered heteroaromatic ring compound and pharmaceutical use thereof
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
FI950309A0 (en) proline amide derivative
FI915819A0 (en) HIV PROTEAS INHIBITOR.
RS20040227A (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
DE60137540D1 (en) METHODS OF TREATING ANXIETY STATE
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
TW200503712A (en) (2-carboxamido)(3-amino)thiophene compounds
ATE316962T1 (en) PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2
WO2001096283A3 (en) Hiv integrase inhibitors
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
TW200505446A (en) Inhibitor of cox
WO2002088091A3 (en) Inhibitors of human rhinovirus 2a cysteine protease
UY26416A1 (en) COMPOUNDS
EA200600608A1 (en) IMIDAZOPIRIDINE DERIVATIVES AS INDUCED NO-SYNTHASE INHIBITORS
AP2002002595A0 (en) Heterocyclic amide derivatives.
TR200100475T2 (en) Production and uses of N-substituted azabicycloheptane derivatives.
DK0985665T3 (en) Process for the preparation of 3-amino-2-oxo-pyrrolidines, intermediates and their use
TW200508211A (en) 2-naphthylimino-1,3-thiazine derivatives
EP2077264A3 (en) Taxane derivatives and a process for the preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP